Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems

Pharmacological Reviews - Tập 68 Số 2 - Trang 419-457 - 2016
Lawrence Toll1,2,3,4,5, Michael R. Bruchas1,2,3,4,5, Girolamo Calò1,2,3,4,5, Brian M. Cox1,2,3,4,5, Nurulain T. Zaveri1,2,3,4,5
1Astraea Therapeutics, LLC, Mountain View, California (N.T.Z.)
2Departments of Anesthesiology, and Neuroscience, Washington University School of Medicine, St. Louis, Missouri (M.R.B.)
3Professor of Pharmacology & Neuroscience, Uniformed Services University, Bethesda, Maryland (B.M.C.)
4Section of Pharmacology, Department of Medical Science, and National Institute of Neurosciences, University of Ferrara, Ferrara, Italy (G.C.)
5Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida (L.T.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

Abdulla, 1998, Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J Neurosci, 18, 9685, 10.1523/JNEUROSCI.18-23-09685.1998

10.1007/978-1-61779-160-4_23

10.1093/jb/mvm100

Al-Hasani, 2011, Molecular mechanisms of opioid receptor-dependent signaling and behavior, Anesthesiology, 115, 1363, 10.1097/ALN.0b013e318238bba6

10.1016/j.neuron.2015.08.019

10.1038/nn1605

10.1097/00001756-199708180-00028

10.1016/j.bmc.2007.04.026

10.1016/S0165-5728(02)00217-5

Armstead, 2002, NOC/oFQ activates PKC and generates superoxide to impair hypotensive cerebrovasodilation after hypoxia/ischemia, Med Sci Monit, 8, BR8

10.1016/j.ejphar.2005.08.059

10.1016/0006-291X(84)90230-4

10.1016/j.neuron.2014.01.044

10.1007/s00210-007-0189-z

10.1016/j.cell.2009.09.028

10.1016/j.peptides.2005.03.016

10.1038/nn1180

10.1038/sj.bjp.0706782

10.1126/science.2402638

10.1016/S0306-4522(03)00484-6

10.1016/0014-2999(96)00238-5

10.1016/j.neuropharm.2004.06.017

10.1007/s002100000220

10.1007/PL00005338

10.1007/s00210-002-0548-8

10.1016/S0196-9781(00)00252-7

10.1124/mol.66.1.106

10.1016/S0306-4522(02)00927-2

10.1016/S0014-2999(02)01833-2

10.1111/j.1471-4159.2006.03902.x

10.1007/s00213-010-1806-y

10.1523/JNEUROSCI.3769-07.2007

10.1016/j.neuron.2011.06.011

10.1016/0014-5793(94)00561-3

10.1213/01.ane.0000250403.88649.51

10.1016/S0196-9781(00)00230-8

Calò G Guerrini R (2013) Medicinal chemistry, pharmacology, and biological actions of peptide ligands selective for teh nociceptin/orphanin FQ receptor, in Research and Development of Opioid-Related Ligands ( Ko MC Husbands SM , eds) pp 275–325, Oxford University Press, Washington, DC.

10.1021/jm970805q

10.1038/sj.bjp.0703169

Calò, 2005, UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor, CNS Drug Rev, 11, 97, 10.1111/j.1527-3458.2005.tb00264.x

10.1038/sj.bjp.0703219

10.1046/j.1440-1681.2002.03633.x

10.1016/0014-2999(96)00563-8

10.1111/j.1755-5949.2009.00107.x

10.1038/sj.bjp.0704706

10.1007/s00210-009-0396-x

10.1073/pnas.0901507106

Chan, 2000, Regulation of c-Jun N-terminal kinase by the ORL(1) receptor through multiple G proteins, J Pharmacol Exp Ther, 295, 1094

Chan, 1998, Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins, J Neurochem, 71, 2203, 10.1046/j.1471-4159.1998.71052203.x

10.1021/acschemneuro.5b00208

10.1038/npp.2013.205

10.1124/mol.115.099150

10.1113/jphysiol.2011.208819

10.1016/j.mcn.2008.09.003

10.1016/0014-2999(79)90142-0

10.1016/0024-3205(78)90077-2

10.1124/jpet.104.070219

10.1124/jpet.106.103960

10.1016/S0014-2999(00)00590-2

10.1007/s00213-003-1645-1

10.1016/j.biopsych.2006.01.006

10.1007/s002130050828

10.1038/npp.2014.113

10.1146/annurev-pharmtox-010611-134548

Combie, 1981, Pharmacology of narcotic analgesics in the horse: selective blockade of narcotic-induced locomotor activity, Am J Vet Res, 42, 716

10.1111/bph.12673

10.1111/j.1469-7793.1998.047bo.x

10.1111/j.1476-5381.1996.tb16080.x

10.1111/j.1476-5381.1996.tb15387.x

10.1210/en.2004-0062

10.1016/S0006-8993(01)02520-3

10.1111/bph.12612

10.1124/jpet.112.194308

10.1016/j.biopsych.2011.10.032

10.1038/sj.bjp.0706066

Daga, 2012, Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation, Proteins, 80, 1948, 10.1002/prot.24077

Dautzenberg, 2001, Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo, J Pharmacol Exp Ther, 298, 812

Davis, 1999, d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia, J Pharmacol Exp Ther, 289, 1048

10.1111/adb.12157

10.1046/j.1460-9568.2003.02676.x

10.1016/0006-8993(96)00476-3

10.1016/S0304-3940(01)02352-7

10.1111/bph.13124

10.1124/mol.112.084632

10.1007/s11481-011-9279-2

10.1016/0024-3205(96)00261-5

Dooley, 1997, Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1, J Pharmacol Exp Ther, 283, 735

10.1016/0014-2999(88)90183-5

10.1016/j.neuroscience.2014.10.037

10.1016/j.biopsych.2008.02.004

10.1016/0304-3959(94)90022-1

10.1007/s00429-014-0717-9

10.1074/jbc.M109.040634

10.1111/j.1476-5381.1996.tb15969.x

10.1038/sj.bjp.0707377

10.1038/nature12944

10.1016/j.ejphar.2009.04.054

10.1016/S0006-8993(00)02669-X

10.1016/S0014-2999(96)00707-8

10.1016/0014-2999(79)90501-6

10.1016/j.neuroscience.2006.09.016

10.1016/0014-5793(94)80603-9

Fukuda, 1998, Activation of phospholipase A2 by the nociceptin receptor expressed in Chinese hamster ovary cells, J Neurochem, 71, 2186, 10.1046/j.1471-4159.1998.71052186.x

10.1007/s00210-006-0035-8

10.1016/j.pharmthera.2013.05.008

10.1046/j.1460-9568.2003.02603.x

10.1016/j.npep.2005.11.002

10.1016/j.biopsych.2014.01.021

10.1007/s00213-012-2636-x

Goldstein, 1969, Tolerance to opioid narcotics. I. Tolerance to the “running fit” caused by levorphanol in the mouse, J Pharmacol Exp Ther, 169, 175

10.1021/jm0509851

10.1016/j.neuroscience.2010.04.033

10.1038/nature11111

10.1021/jm010221v

10.1038/sj.bjp.0701640

10.1016/j.bmc.2014.05.005

10.1016/0165-5728(95)00030-6

10.1016/S0304-3940(97)13401-2

10.1016/S0304-3959(98)00071-2

10.1007/s002100000327

10.1016/S0024-3205(02)01477-7

Hawes, 1998, Nociceptin (ORL-1) and mu-opioid receptors mediate mitogen-activated protein kinase activation in CHO cells through a Gi-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization, J Neurochem, 71, 1024, 10.1046/j.1471-4159.1998.71031024.x

10.1073/pnas.1401819111

10.1016/S0028-3908(01)00048-X

10.1016/j.brainres.2007.12.008

Huang, 2001, Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist, J Pharmacol Exp Ther, 297, 688

10.1124/jpet.112.202184

10.1007/s13311-013-0239-9

10.1007/s00210-008-0350-3

10.1016/S0006-8993(99)01364-5

10.1006/jmbi.2000.4212

10.1016/S0168-0102(01)00230-9

10.1073/pnas.94.26.14854

10.1073/pnas.090514397

Johnson, 1992, Opioids excite dopamine neurons by hyperpolarization of local interneurons, J Neurosci, 12, 483, 10.1523/JNEUROSCI.12-02-00483.1992

10.1016/j.neuropharm.2005.11.010

Judson, 1978, Genetic control of opiate-induced locomotor activity in mice, J Pharmacol Exp Ther, 206, 56

Kallupi, 2014, MT-7716, a novel selective nonpeptidergic NOP receptor agonist, effectively blocks ethanol-induced increase in GABAergic transmission in the rat central amygdala, Front Integr Neurosci, 8, 18, 10.3389/fnint.2014.00018

10.1046/j.1471-4159.2002.01231.x

10.1292/jvms.10-0565

10.1016/j.tibs.2014.03.002

10.1016/j.ejphar.2003.11.061

10.1021/jm990517p

10.1016/S0306-4522(01)00037-9

10.1124/jpet.109.156711

10.1124/jpet.111.184663

10.1016/j.jpain.2008.11.006

10.1124/jpet.301.2.698

10.1124/jpet.106.106120

10.1038/npp.2009.33

10.1016/0014-2999(92)90732-J

10.1016/S0014-2999(03)02081-8

10.1097/00008877-200205000-00006

10.1111/j.1533-2500.2009.00308.x

10.1016/j.ejphar.2007.10.006

10.1038/sj.npp.1301169

10.1124/jpet.102.041350

10.1038/sj.bjp.0705583

Lachowicz, 1995, Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family, J Neurochem, 64, 34, 10.1046/j.1471-4159.1995.64010034.x

10.1093/bja/aeu332

10.1073/pnas.0910705106

10.1016/S0014-5793(98)00452-9

10.1097/00001756-200203250-00018

Lester, 2006, Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes, Brain Res, 1073-1074, 290, 10.1016/j.brainres.2005.12.066

10.1016/j.ejphar.2011.01.057

10.1016/j.ejphar.2009.01.036

10.1038/sj.bjp.0701149

10.1124/jpet.114.213694

Lou, 1998, Nociceptin/orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor, J Neurochem, 70, 1316, 10.1046/j.1471-4159.1998.70031316.x

10.1016/j.pain.2009.11.025

10.1007/s002130000609

Lutfy, 2003, Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors, J Neurosci, 23, 10331, 10.1523/JNEUROSCI.23-32-10331.2003

10.1038/sj.bjp.0704279

10.1007/s00213-002-1192-1

10.1016/j.brainres.2005.01.037

10.1161/01.HYP.33.3.914

10.1124/mol.109.062208

10.1371/journal.pone.0132865

10.1007/s007020100012

10.1038/29073

10.1016/S0014-2999(00)00440-4

10.1124/jpet.102.033159

10.1124/jpet.103.051599

10.1038/nature10954

10.1002/cne.903500307

10.1016/j.neuropharm.2007.11.003

10.1016/S0306-4522(02)00050-7

10.1111/j.1476-5381.2012.02219.x

10.1523/JNEUROSCI.2546-05.2005

10.1111/j.1471-4159.2004.02843.x

10.1523/JNEUROSCI.6408-11.2012

10.1002/mds.23271

10.1038/sj.bjp.0705005

10.1523/JNEUROSCI.4346-06.2007

10.1038/sj.bjp.0705401

10.1007/s00210-002-0661-8

10.1159/000077448

10.1159/000328782

10.1111/j.1460-9568.2004.03220.x

10.1073/pnas.1000751107

10.1124/mol.53.4.772

10.1016/S0196-9781(00)00225-4

10.1038/377532a0

10.1016/j.ejphar.2015.02.020

10.1016/j.peptides.2007.09.004

10.1073/pnas.91.19.9081

10.1016/j.celrep.2013.10.015

10.1016/0306-4522(96)00338-7

10.1016/0304-3940(96)12917-7

10.1111/j.1476-5381.2012.02115.x

Molinari S, Malfacini D, Camarda V, Trapella C, Guerrini R, Mustazza C, and Calo G (2012) In vitro pharmacological characterization of the non peptide NOP receptor agonists Ro 65-6570, SCH-221510 and Compound 6d, in BPS Focused Meeting on Neuropeptides, http://www.pa2online.org, King's College London, UK.

10.1073/pnas.93.16.8666

10.1016/0014-5793(96)00993-3

10.1124/mol.55.2.324

10.1016/0014-5793(94)80235-1

10.1016/S0196-9781(00)00235-7

10.1016/j.euroneuro.2015.03.006

10.1146/annurev.cellbio.13.1.261

10.1016/j.pbb.2006.08.003

10.1097/00001756-199711100-00003

10.1002/mds.26103

10.1124/mol.57.3.495

10.1113/jphysiol.2012.228429

10.1016/S0006-8993(99)01425-0

10.1016/0306-4522(96)00322-3

10.1046/j.1471-4159.1999.0730179.x

10.1002/med.20197

10.1038/sj.bjp.0702907

10.1016/j.neuropharm.2009.09.004

10.1002/(SICI)1096-9861(19991004)412:4<563::AID-CNE2>3.0.CO;2-Z

10.1002/(SICI)1096-9861(19990419)406:4<503::AID-CNE7>3.0.CO;2-P

10.1523/JNEUROSCI.1259-08.2008

10.1016/j.ejphar.2006.07.015

10.1002/cne.10154

10.1073/pnas.93.16.8677

Nugent, 1982, Effects of enkephalins versus opiates on locomotor activity of the horse, Res Commun Chem Pathol Pharmacol, 35, 405

10.1016/j.tips.2009.02.006

10.1016/j.pain.2005.03.012

10.1006/bbrc.2000.3822

10.1111/j.1471-4159.2008.05629.x

10.1074/jbc.M406405200

10.1016/S0014-2999(00)00520-3

10.1016/S0014-2999(99)00822-5

10.1523/JNEUROSCI.5122-14.2015

10.1124/mol.105.011536

10.1016/S0006-291X(02)02258-1

Pan, 1995, Cloning and functional characterization through antisense mapping of a κ 3-related opioid receptor, Mol Pharmacol, 47, 1180

10.1016/S0014-5793(98)01039-4

10.1016/S0896-6273(00)81183-6

10.1159/000317070

10.1016/S0165-5728(97)00178-1

10.1523/JNEUROSCI.1227-12.2012

10.1016/S0196-9781(00)00243-6

10.1517/14656566.2013.784269

Post A Smart TS Krikke-Workel J Dawson GR Harmer CJ Browning M Jackson K Kakar R Mohs R Statnick M (2015) A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology, in press.

10.1016/j.jpainsymman.2006.05.013

10.1038/sj.onc.1210392

10.1007/s00210-001-0511-0

10.1074/jbc.271.24.14163

10.1126/science.270.5237.792

10.1016/j.ejphar.2007.10.031

10.1016/S0014-2999(99)00730-X

10.1007/s002100000358

10.1124/jpet.106.116780

10.1111/bph.12799

10.1097/00001756-200110080-00006

10.1016/j.neuropharm.2010.12.010

10.1038/sj.bjp.0704894

10.1007/s00210-002-0549-7

10.1016/j.peptides.2007.04.020

10.1111/bph.13150

10.1007/s002100100399

10.1124/jpet.300.1.57

10.1038/sj.bjp.0704523

10.1124/jpet.105.089284

10.1016/j.ejphar.2010.07.036

Rutten, 2011, Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats, Drug Alcohol Depend, 114, 253

10.1007/s00213-003-1643-3

10.1111/j.1460-9568.1997.tb01367.x

10.1016/j.brainres.2003.11.008

10.1016/j.cell.2009.04.019

10.1073/pnas.0603359103

10.1016/S0196-9781(00)00233-3

10.1111/bph.12744

10.1021/ml500117c

10.1016/j.peptides.2009.12.028

10.1111/j.1527-3458.2007.00007.x

10.1016/j.neuropharm.2005.04.008

10.1016/S0143-4179(98)90087-7

10.1038/nature13430

10.1097/00001756-199602290-00012

10.1038/sj.bjp.0702793

10.1016/j.neuron.2015.03.066

10.1124/jpet.106.116764

10.1007/s000180200016

10.1097/00001756-200110080-00035

10.1111/j.1476-5381.1996.tb15618.x

Stayte, 2014, Advances in non-dopaminergic treatments for Parkinson’s disease, Front Neurosci, 8, 113

10.1007/s00213-013-3341-0

10.1152/ajplung.00358.2012

10.1016/S0304-3940(01)02095-X

10.1016/S0304-3940(03)00502-0

10.1016/j.ejphar.2005.01.033

Tancredi, 2005, The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ, Chemistry, 11, 2061, 10.1002/chem.200401095

10.1016/j.pharmthera.2014.02.004

10.1016/S0028-3908(02)00145-4

10.1016/S0169-328X(02)00390-X

10.1038/nature11085

10.1016/S0196-9781(00)00242-4

10.1124/jpet.109.157446

10.1093/protein/11.12.1163

10.1016/j.bmc.2005.08.049

10.1016/j.peptides.2005.03.015

10.1126/science.1824728

10.1016/S0304-3940(97)00832-X

10.1016/j.brainres.2005.05.044

10.1038/35041572

10.1007/s002109900074

10.1016/j.neuron.2015.03.065

10.1007/s00213-005-0041-4

10.1124/jpet.108.136937

10.1111/j.1476-5381.1996.tb15329.x

Vaughan, 1997, Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro, J Neurosci, 17, 996, 10.1523/JNEUROSCI.17-03-00996.1997

10.1016/j.ejphar.2012.11.050

10.1074/jbc.M113.474452

10.1016/j.neuropharm.2013.04.046

10.1016/j.nbd.2008.02.011

10.1016/j.expneurol.2010.12.024

10.1038/nature11810

10.1126/science.1232808

10.1097/00001756-199807130-00017

10.1016/j.cellsig.2005.06.009

10.1111/j.1471-4159.2004.02921.x

10.1016/0014-5793(94)00557-5

Wang, 1996, Nociceptin (orphanin FQ), an endogenous ligand for the QRL1 (opioid-receptor-like1) receptor; modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli, J Neurophysiol, 76, 3568, 10.1152/jn.1996.76.5.3568

10.1038/sj.bjp.0702534

10.1016/j.molmed.2010.11.004

10.1016/S0960-894X(99)00385-6

10.1016/S0223-5234(00)00171-9

10.1016/0169-328X(95)00096-B

Wickman, 1995, Ion channel regulation by G proteins, Physiol Rev, 75, 865, 10.1152/physrev.1995.75.4.865

10.1124/pr.112.005942

10.1016/j.pharmthera.2013.10.011

10.1089/089771503767168456

10.1124/mol.56.2.334

10.1016/S0304-3940(03)00518-4

10.1038/nature10939

10.1016/S0169-328X(00)00033-4

10.1016/S0022-2836(02)01283-4

10.1016/j.jmb.2005.09.040

10.1172/JCI35115

Xu, 1996, Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat, Neuroreport, 7, 2092

10.1038/sj.bjp.0704478

10.1038/sj.bjp.0705371

10.1016/S0306-4522(97)00166-8

10.1097/00001756-200410050-00012

Yoshimura, 1989, Primary afferent-evoked synaptic responses and slow potential generation in rat substantia gelatinosa neurons in vitro, J Neurophysiol, 62, 96, 10.1152/jn.1989.62.1.96

10.1002/(SICI)1098-1063(1997)7:1<88::AID-HIPO9>3.0.CO;2-3

Yung, 1999, GalphaL1 (Galpha14) couples the opioid receptor-like1 receptor to stimulation of phospholipase C, J Pharmacol Exp Ther, 288, 232

Zaki, 2000, Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?, J Pharmacol Exp Ther, 292, 1127

10.1016/S0959-4388(98)80060-3

10.1124/mi.2.8.476

10.1124/jpet.103.055848

10.2174/156802611795371341

10.1124/jpet.102.046979

10.1021/jm0202021

10.1074/jbc.M112.405696

10.1186/1744-8069-8-76

10.1111/bph.12701

10.1046/j.1471-4159.1999.0731502.x

10.1097/00001756-200312190-00019

10.1073/pnas.0705740104

10.1038/npp.2010.116